Showing 1621-1630 of 4063 results for "".
- Euclid Vision Announces Official Launch of Cloud-Based Portalhttps://modernod.com/news/euclid-vision-announces-official-launch-of-cloud-based-portal/2480964/Euclid Vision has announced the official rollout of MyEuclid, an interactive, web-based customer portal designed to drive practice efficiency and optimize Euclid Ortho-K fits. The MyEuclid portal was released on a limited basis earlier this year, and the platform is now availa
- ASRS Announces Virtual Annual Scientific Meeting July 24-26, 2020https://modernod.com/news/asrs-announces-virtual-annual-scientific-meeting-july-24-26-2020/2477759/Due to the COVID-19 pandemic, the American Society of Retina Specialists (ASRS) has decided to hold its annual meeting online. In a letter to membership, Timothy Murray, MD, MBA, ASRS President, and Philip Ferrone, MD, Program Chair, said that the ASRS Board of Directors has concluded that
- Strategic National Stockpile Aims to Get 400M Syringes by December for COVID-19 Vaccine: Officialshttps://modernod.com/news/strategic-national-stockpile-aims-to-get-400m-syringes-by-december-for-covid-19-vaccine-officials/2477888/Trump administration officials want to stockpile 400 million syringes and needles by December in anticipation of a COVID-19 vaccine, according to a FierceHealthcare report. Administration officials testified before Congress on Tuesday on the procurement of supplies during the COVID-19 pand
- ASCRS Officially Cancels Its Annual Meetinghttps://modernod.com/news/ascrs-officially-cancels-its-annual-meeting/2477401/The American Society of Cataract and Refractive Surgery (ASCRS) is cancelling its annual meeting originally scheduled for May 15-20 in Boston. Through a statement po
- Hovione Completes Phase 2 Clinical Trial of First Minocycline Ophthalmic for Dry Eye Disease Associated With Inflamed MGDhttps://modernod.com/news/hovione-completes-phase-2-clinical-trial-of-first-minocycline-ophthalmic-showing-promise-in-dry-eye-disease-associated-with-inflamed-mgd/2478986/Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its phase 2 clinical trial in 270 patients with dry eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in
- Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Resultshttps://modernod.com/news/isarna-therapeutics-presents-positive-phase-2-better-trial-final-results-at-arvo-2025/2482797/Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data
- Despite Impressive Data, FDA’s Coronavirus Vaccine Reviews Will Take Weeks, Not Days, Official Sayshttps://modernod.com/news/despite-impressive-data-fdas-coronavirus-vaccine-reviews-will-take-weeks-not-days-official-says/2478574/As leading COVID-19 vaccines post positive phase 3 data and near FDA submissions, the agency official in charge of reviewing vaccines is emphasizing transparency and patience during the high-stakes process, according to a FiercePharma
- Aviceda Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for GAhttps://modernod.com/news/aviceda-therapeutics-announces-first-patient-dosed-in-part-2-of-the-phase-23-siglec-trial-assessing-avd-104-for-ga/2482092/Aviceda Therapeutics announced it has dosed the first patient in part 2 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “Based on the efficacy and safety we saw in part 1, we moved rapidly to i
- Phase 2 Study Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to AMDhttps://modernod.com/news/phase-2-study-highlights-efficacy-and-safety-data-of-intravitreal-apl-2-for-geographic-atrophy-secondary-to-amd/2476891/Apellis Pharmaceuticals announced details about its phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in Ophth
- ProQR Reports First Patient Dosing in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-reports-first-patient-dosing-in-phase-1-2-stellar-trial-of-qr-421a-for-usher-syndrome-type-2/2476365/ProQR Therapeutics announced the first patient dosed in the phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019. “There are no effective treat